Polymorphisms of CYP1B1 and COMT in breast and endometrial cancer

Molekulyarnaya Biologiya

Volumn 38, Issue 3, 2004, Pages 386-393

  Zimarina, T S ^a   Kristensen, V N ^a   Imyanitov, E N ^a   Berstein, L M ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1B1; ESTRADIOL; GLYCINE; LEUCINE; METHIONINE; SERINE; VALINE; CYTOCHROME P 450 CYP1B1; CYTOCHROME P-450 CYP1B1; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYDROXYLATION; MAJOR CLINICAL STUDY; MAMMARY GLAND; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; BREAST TUMOR; ENDOMETRIUM TUMOR; ENZYMOLOGY; FEMALE; GENETICS; RISK FACTOR;

ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CATECHOL O-METHYLTRANSFERASE; ENDOMETRIAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 6944246606     PISSN: 00268984     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Feigelson H.S., Henderson B.E. 1996. Estrogens and breast cancer. Carcinogenesis (Lond.). 17, 2279-2284.
2. Kelsey J.L., Gammon M.D. 1991. The epidimiology of breast cancer. Cancer J. Clin. 41, 146-165.
3. Cavalieri E.L., Stack D.E., Devanesan P.D., Tolorovic R., Dwivedy I., Higginbothan S., Johansson S.L., Patil K.D., Gross M.L., Coolen J.K. 1997. Molecular origin of cancer: catechol estrogen-3.4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. USA. 94, 10937-10942.
4. Shimada T., Hayes C.L., Yamazaki H., Amin S., Hecht S.S. 1996. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res. 56, 2979-2985.
5. Hayes C.L., Spink D.C., Spink B.C., Cao J.O., Walker N., Satter T.R. 1996. 17beta-estradiolhydroxylation catalyzed by human cytochrome P4501B1. Proc. Natl. Acad. Sci. USA. 93, 9776-9781.
6. Spink D.C., Eugster H.P., Lincoln II D.W., Schuetz J.D., Schuetz E.G., Johnson J.A., Kaminsky L.S., Girthy J.F. 1992. 17beta estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2.3,7.8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterolocous expression of DNA. Arch. Biochem. Biophys. 293, 342-348.
7. Spink D.C., Spink B.C., Cao J.O., Girthy J.F., Hayes C.L., Li Y., Satter T.R. 1997. Induction of cytochrome P450 1B1 and catecholoestrogen metabolism in ACHN human renal adenocarcinoma cells. J. Steroid Biochem. Mol. Biol. 62, 223-232.
8. Liehr J.G., Ricci M.J. 1996. 4-hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. USA. 93, 3294-3296.
9. Huang Z., Fasco M.J., Figge H.L., Keyomarsi K., Kaminsky L.S. 1996. Expression of cytochtome P450 1B1 in human breast tissue and tumors. Drug Metab. Dispos. 24, 899-905.
10. Murray G.I., Taylor M.C., McFadyen M.C., McKey J.A., Greenlee W.F. 1997. Tumor specific expression of cytochrome P450 1B1. Cancer Res. 57, 3026-3031.
11. Cheung Y-L., Kerr A.C., McFadyen M.C.E., Melvin W.T., Murray G.I. 1999. Differential expression of CYP1A1, CYP1A2 and CYP1B1 in human kidney tumors. Cancer Lett. 139, 199-205.
12. Reider C.R.M., Ramsden D.B., Williams A.L. 1998. Cytochrome P450 1B1 mRNA in the human central nervous system. J. Clin. Pathol. Mol. Pathol. 51, 138-142.
13. Bailey L.R., Roody N., Dupont W.D., Parl F.F. 1998. Association of cytochrome P450 1B1 polymorphism with steroid receptor status in breast cancer. Cancer Res. 58, 5038-5041.
14. Inoue K., Asao T., Shimada T. 1999. Ethnic related differences in frequency distribution of genetic polymorphism in CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations. Xenobiotika. 30, 285-295.
15. Stoilov I., Akarsu A.N., Alozie I., Child A., Barsoum-Homsy H., Turadi M.E., Lewis K.A., Ozdemir N., Brice G., Aktan S.G., Chevrette L., Coca-Prados M., Sarfarazi M. 1998. Sequence analysis and homology modeling suggests that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P450 1B1. Am. J. Hum. Genet. 62, 573-584.
16. Li D.N., Seidel A., Pritchard M.P., Wolf C.R., Friedberg T. 2000. Polymorphisms in P450 1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4 - hydroxyestradiol. Pharmacogenetics. 10, 343-353.
17. Hanna I.H., Dawling S., Roodi N., Guengerich F.P., Parl F.F. 2000. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in oestrogen hydroxylation activity. Cancer Res. 60, 3440-3444.
18. Shimada T., Watanabe J., Kawajiri K., Sutler T.R., Guengerich P.P., Gillam E.M.J., Inoue K. 1999. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 20, 1607-1613.
19. Shimada T., Watanabe J., Inoue K., Guengerich F.P., Gillam E.M. 2001. Specificity of 17 beta-estradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P450 1B1 variants substituted at residues 48, 119 and 432. Xenobiotica. 31, 163-176.
20. Zheng W., Xie D.W., Jin F., Cheng J.L., Dai Q., Wen W.Q., Shu X.O., Gao V.T. 2000. Genetic polymorphism of cytochrome P450 1B1 and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 9, 147-150.
21. De Vivo I., Hankinson S.E., Li L., Colditz G.A., Hunter D.J. 2002. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 489-492.
22. Thier R., Bruning T., Roos P.H., Bolt H.M. 2002. Cytochrome P450 1B1, a new keystone in gene environment interactions related to human head and neck cancer? Arch. Toxicol. 76, 249-256.
23. Goodman M.T., Mc Duffie K., Kolonel L.N., Terada K., Domlon T.A., Wilkens L.R., Guo G., Le Marcand L. 2001. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol. Biomarkers Prev. 10, 209-216.
24. Tang Y.M., Green B.L., Chen G.F., Thompson P.A., Lang N.P., Shinde A., Lin D.X., Tan W., Lyn-Cook B.D., Hammons G.J., Kadlubar F.F. 2000. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese: estradiol hydroxylase activity, and distribution in prostate cancer cases and controls. Pharmacogenetics. 10, 761-766.
25. Watanabe J., Shimada T., Gillam E.M.J., Ikuta T., Suemasu K., Higashi Y., Gotoh O., Kawajiri K. 2000. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics. 10, 25-33.
26. Lachman H.M., Papolos D.F., Saito T., Yu Y.-M., Szumlanski C.L., Weinshilboum R.M. 1996. Human catechol-o-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric diseases. Pharmacogenetics. 6, 243-250.
27. Thompson P.A., Shields P.G., Freudenheim J.L., Stone A., Vena I.E., Marshall J.R., Graham S., Laughlin R., Nemoto T., Kadlubar F.F., Ambrosone C.B. 1998. Genetic polymorphism in catechol-o-methyltransferase, menopausal status and breast cancer risk. Cancer Res. 58, 2107-2110.
28. Huang C.-S., Chern H.D., Chang K.J., Cheng C.-W., Hsu S.-M., Shen C.Y. 1999. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1 and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59, 4870-4875.
29. Lavigne J.A., Helzlisouer K.J., Huang H.-Y., Strikland P.T., Bell D.A., Selmin O., Watson M.A., Hoffman S., Comstock G.L.V., Yager J.D. 1997. An association between the allele coding for a low activity variant of catechol-o-methyltransferase and the risk for breast cancer. Cancer Res. 57, 5493-5497.
30. Matsui A., Ikeda T., Enomoto K., Nakashima H., Omae K., Watanabe M., Hibi T., Kitajima M. 2000. Progression of human breast cancers to the metastatic state in linked to genotypes of catechol-o-methyltransferase. Cancer. Lett. 150, 23-31.
31. Millikan R.C., Pittman G.S., Tse C.K.J., Duell E., Newman B., Savitz D., Moorman P.G., Boissy R.J., Bell D.A. 1998. Catechol-o-methyltransferase and breast cancer risk. Carcinogenesis. 19, 1943-1947.
32. Yim D.S., Park S.K., Yao K.Y., Yoon K.S., Chung H.H., Kang H.L., Ahn S.H., Noh D.Y., Choe K.J., Jang I.J., Shin S.G., Striklamd P.T., Hivronen A., Kang D. 2001. Relationship between the Val158Met polymorphism of COMT and breast cancer risk. Pharmacogenetics. 11, 279-286.
33. Mitrunen K., Jourenkova N., Kataja V., Eskelinen M., Kosma V.M., Benhamou S., Kang D., Vainio H., Uusitupa M., Hirvonen A. 2001. Catechol-o- methyltransferase in finnish population. Carcinogenesis, Cancer Epidemiol. Biomarkers Prev. 10, 635-640.
34. Mullenbach R., Lagoda P.J., Welter C. 1989. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet. 5, 391-397.
35. Berstein L.M., Imyanitov E.N., Suspitsin E.N., Grigoriev M.Y., Togo A.V., Hanson K.P., Kovalevskij A.Y. 2001. CYP19 gene polymorphism in endometrial cancer patients. J. Cancer. Res. Clin. Oncol. 127, 135-138
36. Berstein L.M., Imyanitov E.N., Suspitsin E.N., Kovalevskij A.Y., Grigoriev M.Y., Togo A.V., Hanson K.P. 2002. CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? Cancer Lett. 180, 47-53.